Cesamet en es it fr

Cesamet Brand names, Cesamet Analogs

Cesamet Brand Names Mixture

  • No information avaliable

Cesamet Chemical_Formula


Cesamet RX_link


Cesamet fda sheet

Cesamet msds (material safety sheet)

Cesamet MSDS

Cesamet Synthesis Reference

No information avaliable

Cesamet Molecular Weight

357.443 g/mol

Cesamet Melting Point

230 oC as HCl salt

Cesamet H2O Solubility

35.5 mg/mL at 25 oC as HCl salt

Cesamet State


Cesamet LogP


Cesamet Dosage Forms

Solution (suitable for subcutaneous, intramuscular, or intravenous injection - available as 10 mg or 20 mg of nalbuphine hydrochloride per mL)

Cesamet Indication

For the relief of moderate to severe pain.

Cesamet Pharmacology

Nalbuphine is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. Nalbuphine's analgesic potency is essentially equivalent to that of morphine on a milligram basis. The opioid antagonist activity of nalbuphine is one-fourth as potent as nalorphine and 10 times that of pentazocine. Nalbuphine by itself has potent opioid antagonist activity at doses equal to or lower than its analgesic dose. When administered following or concurrent with mu agonist opioid analgesics (e.g., morphine, oxymorphone, fentanyl), nalbuphine may partially reverse or block opioid-induced respiratory depression from the mu agonist analgesic. Nalbuphine may precipitate withdrawal in patients dependent on opioid drugs. Nalbuphine should be used with caution in patients who have been receiving mu opioid analgesics on a regular basis.

Cesamet Absorption

The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.

Cesamet side effects and Toxicity

ORAL (LD50): Acute: 1100 mg/kg [Dog]. Symptoms of overdose include primarily sleepiness and mild dysphoria.

Cesamet Patient Information

Cesamet Organisms Affected

Humans and other mammals